Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Cancer Research

• Publication date

  1995-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 7627974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytokine Signal Transduction through a Homo‐or Heterodimer of gp130

  1995cited by this paper
• Interleukin-5 (IL-5) increases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression and is inhibited by IL-4.

  1994cited by this paper
• Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors.

  1994cited by this paper
• Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.

  1994cited by this paper
• v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells.

  1994cited by this paper
• Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.

  1994cited by this paper
• Cytokine signal transduction.

  1994cited by this paper
• Deletion of the retinoblastoma gene in multiple myeloma.

  1994cited by this paper
• Mediation of c-Myc-induced apoptosis by p53.

  1994cited by this paper
• Infection with a Kirsten-retrovirus can induce a multiplicity of tumorigenic phenotypes in the interleukin-3-dependent FDC-P1 cells.

  1994cited by this paper
• The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell

  1993cited by this paper
• Function and regulation of ras.

  1993cited by this paper
• Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.

  1993influential reference
• Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

  1993cited by this paper
• Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications.

  1993cited by this paper
• Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients.

  1992cited by this paper
• Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active Ras.GTP complex in rat pheochromocytoma PC12 cells.

  1992cited by this paper
• Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides

  1992cited by this paper
• Mutations of the p53 gene in human myeloma cell lines.

  1992cited by this paper
• Features of apoptotic cells measured by flow cytometry.

  1992cited by this paper
• Cytokine network in human multiple myeloma.

  1992cited by this paper
• Anti‐human interleukin‐6 receptor antibody inhibits human myeloma growth in vivo

  1992cited by this paper
• A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs.

  1992cited by this paper
• p53 and RAS gene mutations in multiple myeloma.

  1992cited by this paper
• Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266.

  1991cited by this paper
• Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4.

  1991cited by this paper
• Cooperation between oncogenes.

  1991cited by this paper
• A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.

  1991cited by this paper
• Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

  1991cited by this paper
• The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.

  1990cited by this paper
• Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.

  1990cited by this paper
• Oncogenes in multiple myeloma: point mutation of N-ras.

  1990cited by this paper
• IL-6 as a growth factor for human multiple myeloma cells--a short overview.

  1990cited by this paper
• Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A.

  1990cited by this paper
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

  1990cited by this paper
• Interleukin-6: historical background, genetics and biological significance.

  1990cited by this paper
• Improved Retroviral Vectors for Gene Transfer and Expression

  1989cited by this paper
• A mutant RAS gene acts through protein kinase C to augment interleukin-3 dependent proliferation in a fastidious immortal myeloid cell line.

  1989cited by this paper
• Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

  1989cited by this paper
• Ras oncogene mutation in multiple myeloma

  1989cited by this paper
• A v-H-ras-dependent hemopoietic tumor model involving progression from a clonal stage of transformation competence to autocrine interleukin 3 production

  1989cited by this paper
• Improved retroviral vectors for gene transfer and expression.

  1989cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

  1989cited by this paper
• Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes.

  1989cited by this paper
• Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies.

  1988cited by this paper
• Analysis of RAS oncogene mutations in human lymphoid malignancies.

  1988cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper
• Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

  1988cited by this paper
• Mutations in N-ras predominate in acute myeloid leukemia.

  1987cited by this paper
• Distinct short‐lived and long‐lived antibody‐producing cell populations

  1986cited by this paper
• Human N-ras: cDNA cloning and gene structure.

  1985cited by this paper
• Enhancing the efficiency of DNA-mediated gene transfer in mammalian cells

  1981cited by this paper
• Involvement of ras p 21 protein in signal-transduction pathways from interleukin 2 , interleukin 3 , and granulocyte / macrophage colony-stimulating factor , but not from interleukin 4 ( growth factor receptor / lymphokine / cytokine )

  year unknowncited by this paper

• FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations

  2023cites this paper
• Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

  2022cites this paper
• secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics

  2022cites this paper
• Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis

  2019cites this paper
• Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple Myeloma

  2019cites this paper
• Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.

  2018cites this paper
• Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

  2017cites this paper
• Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation.

  2015cites this paper
• MNK1-Induced eIF-4E Phosphorylation in Myeloma Cells: A Pathway Mediating IL-6-Induced Expansion and Expression of Genes Involved in Metabolic and Proteotoxic Responses

  2014cites this paper
• Staging and prognostication of multiple myeloma

  2014cites this paper
• plasma cell tumors transition and in the intramedullary to extramedullary transition in some Possible roles for activating RAS mutations in the MGUS to MM

  2013cites this paper
• Myeloma: classification and risk assessment.

  2013cites this paper
• chemoresistance expression which participates in enhanced adhesion to fibronectin and Oncogenic ras mutations in myeloma cells selectively induce COX-2

  2013cites this paper
• Cytogenetics and Chromosomal Abnormalities in Multiple Myeloma-A Review

  2013cites this paper
• The role of natural killer cells in immunity against multiple myeloma

  2012cites this paper
• From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma

  2011cites this paper
• Constitutive NF-κB Activation Confers Interleukin 6 (IL6) Independence and Resistance to Dexamethasone and Janus Kinase Inhibitor INCB018424 in Murine Plasmacytoma Cells*

  2011cites this paper
• Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

  2010cites this paper
• Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo

  2010cites this paper
• multiple myeloma Different CD44 splicing patterns define prognostic subgroups in

  2009cites this paper
• The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma

  2009cites this paper
• IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.

  2008cites this paper
• Tumors Apoptosis in MMTV-myc and MMTV-ras Mouse Mammary Differential Regulation of Cell Cycle Characteristics and Updated Version

  2006cites this paper
• Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

  2006influential citation
• Assessing the consequences of hurricane-induced fragmentation of mangrove forest on habitat and nekton in Big Sable Creek, Florida

  2006cites this paper
• N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma

  2006cites this paper
• Regulation of transcription and analysis of drug targets in lymphoma and myeloma cells

  2006cites this paper
• New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway.

  2006cites this paper
• Activating Mutations in the Nand Kras Oncogenes Differentially Affect the Growth Properties of the IL-6-dependent Myeloma Cell Line ANBL 6 '

  2006cites this paper
• Advances in Brief Differential Regulation of Cell Cycle Characteristics and Apoptosis in MMTV-myc and MMTV-ras Mouse Mammary Tumors '

  2006cites this paper
• Targeting aurora kinases as therapy in multiple myeloma.

  2006cites this paper
• Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.

  2005cites this paper
• Geranylgeranylated proteins are involved in the regulation of myeloma cell growth.

  2005cites this paper
• Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.

  2004cites this paper
• Molecular biology and cytogenetics

  2004cites this paper
• Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

  2004cites this paper
• Multistep Tumorigenesis of Multiple Myeloma: Its Molecular Delineation

  2003cites this paper
• Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.

  2003cites this paper
• Farnesyl Transferase Inhibitors Enhance Death Receptor Signals and Induce Apoptosis in Multiple Myeloma Cells

  2003cites this paper
• An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth

  2003cites this paper
• Downstream effectors of oncogenic ras in multiple myeloma cells.

  2003cites this paper
• Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non‐functional variant transcript

  2003cites this paper
• Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.

  2003cites this paper
• Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system.

  2003cites this paper
• The biology and cytogenetics of multiple myeloma.

  2002cites this paper
• Multiple Myeloma Cell Lines

  2002cites this paper
• Molecular aspects of multiple myeloma

  2002cites this paper
• Activating Mutations of Nand Kras in Multiple Myeloma Show Different Clinical Associations : Analysis of the Eastern Cooperative Oncology Group Phase I 11 Trial

  2002cites this paper
• Myeloid cell factor-1 is a critical survival factor for multiple myeloma.

  2002cites this paper
• Chromosomal and genetic abnormalities in myeloma

  2002influential citation
• Proliferation of IL‐6‐independent multiple myeloma does not require the activity of extracellular signal‐regulated kinases (ERK1/2)

  2002cites this paper
• Multiple myeloma: evolving genetic events and host interactions

  2002cites this paper
• New developments and treatment in multiple myeloma: new insights on molecular biology.

  2002cites this paper
• Chromosomal and genetic abnormalities in myeloma.

  2002cites this paper
• Chromosomal and genetic abnormalities in myeloma.

  2002cites this paper
• Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response

  2002cites this paper
• Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma.

  2001cites this paper
• Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.

  2001cites this paper
• High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

  2001influential citation
• Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

  2001cites this paper
• The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

  2001cites this paper
• Affect T Cell and NK Cell Activation Specific Subdomains of Vav Differentially

  2000cites this paper
• Cutting Edge: WIP, a Binding Partner for Wiskott-Aldrich Syndrome Protein, Cooperates with Vav in the Regulation of T Cell Activation1

  2000cites this paper
• Insulin‐like growth factor induces the survival and proliferation of myeloma cells through an interleukin‐6‐independent transduction pathway

  2000cites this paper
• JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells

  2000cites this paper
• Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells.

  2000cites this paper
• Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

  2000cites this paper
• Cell Activation Cooperates with Vav in the Regulation of T Wiskott-Aldrich Syndrome Protein , Cutting Edge : WIP , a Binding Partner for

  2000cites this paper
• Specific Subdomains of Vav Differentially Affect T Cell and NK Cell Activation1

  2000cites this paper
• The role of Ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation

  2000cites this paper
• Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors

  2000cites this paper
• Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

  2000cites this paper
• Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.

  2000cites this paper
• Molecular aspects of multiple myeloma.

  2000cites this paper
• The biology of multiple myeloma

  2000cites this paper
• The role of adhesion receptors in the pathogenesis of multiple myeloma.

  1999cites this paper
• Carcinogenesis in the biliary system associated with APDJ.

  1999cites this paper
• Mechanisms of myeloma cell growth control.

  1999cites this paper
• Analysis of the c‐myc, K‐ras and p53 Genes in Methylcholanthrene induced Mouse Sarcomas

  1999cites this paper
• Expression of fibroblast growth factor receptor 3 in multiple myeloma causes II-6-independence and enhanced survival

  1999cites this paper
• Interferon-α protects myeloma cell lines from dexamethasone-induced apoptosis

  1999cites this paper
• Increased tumor cell proliferation in murine tumors with decreasing dosage of wild‐type p53

  1999cites this paper
• Essential role of STAT3 for embryonic stem cell pluripotency.

  1999cites this paper
• Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis.

  1999cites this paper
• Anomalous junction of the pancreaticobiliary duct accompanied by gallbladder cancer and obstructive jaundice in a patient with high serum and bile cytokine levels

  1998cites this paper
• Biological significance of heterogeneity in human myeloma cells.

  1998cites this paper
• IL-2-induced cellular events.

  1998cites this paper
• Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity

  1998cites this paper
• Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

  1998cites this paper
• Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells.

  1998cites this paper
• [Genetic control of programmed cell death (apoptosis). Prospects for biological tumor staging?].

  1998cites this paper
• Fas/Fas ligand (FasL)‐deregulated apoptosis and IL‐6 insensitivity in highly malignant myeloma cells

  1998cites this paper
• Die genetische Kontrolle des programmierten Zelltods (Apoptose) Perspektiven für ein biologisches Tumorstaging?

  1998cites this paper
• Multiple myeloma: new aspects of biology and treatment.

  1998cites this paper
• Biology of the Transition of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma.

  1998cites this paper
• Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.

  1998cites this paper
• Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells.

  1998cites this paper
• A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis

  1998cites this paper
• Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors.

  1997cites this paper
• Activation of the K‐ras oncogene in colorectal neoplasms is Associated with decreased apoptosis

  1997cites this paper